Immunovant (IMVT) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $6.31B and a free-cash-flow yield of -7.3%. Nama's AI scorecard rates it Sell, 2.2 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Sell · 2.2/10
Clearly negative, short of the bottom band. As of Nov 7, 2026.
Momentum
Rising · +35.4% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-33.0%
How far the last close sits under the highest price of the past five years.
Market cap
$6.31B
Trailing P/E
—
Price / book
8.6
Price / sales
—
FCF yield
-7.3%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.8
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
IMVT earnings
Next report: Nov 9, 2026 (Q2 2027, EPS estimate -$0.72).
Beat the EPS estimate in 2 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q1 2027
Aug 6, 2026
-$0.68
-$0.61
-11.5%
$0
Q4 2026
May 20, 2026
-$0.67
-$0.63
-6.3%
$0
Q3 2026
Feb 6, 2026
-$0.54
-$0.69
+21.7%
$0
Q2 2026
Nov 10, 2025
-$0.65
-$0.73
+11.0%
$0
IMVT analyst price target
Median target $48.50 from 16 analysts, ranging $30.00 – $66.00.
Nama's AI scorecard currently rates Immunovant Sell (2.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does IMVT report earnings?
Immunovant's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.72.
What is the IMVT price target?
The median analyst price target from 16 analysts is $48.50, with a range of $30.00 – $66.00.
Is IMVT Shariah compliant?
Nama's AAOIFI-style screen reads Immunovant as Can't Tell. A figure the screen needs is missing, so it can't tell.